Skip to content 
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. more
| Time Frame | NMRA | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -12.11% | -0.09% | 0.04% |
| 1-Month Return | -23.74% | -1.15% | 4.2% |
| 3-Month Return | -52.01% | -7.34% | 7.84% |
| 6-Month Return | -34.25% | -4.34% | 11.44% |
| 1-Year Return | 141.85% | 8.45% | 24.16% |
| 3-Year Return | -90.18% | 10.97% | 76.54% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Cost of Revenue | 1.55M | 2.70M | 668.00K | - | 5.00M | [{"date":"2021-12-31","value":31.02,"profit":true},{"date":"2022-12-31","value":53.94,"profit":true},{"date":"2023-12-31","value":13.36,"profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | (1.55M) | (2.70M) | (668.00K) | - | (5.00M) | [{"date":"2021-12-31","value":-155100000,"profit":false},{"date":"2022-12-31","value":-269700000,"profit":false},{"date":"2023-12-31","value":-66800000,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":-500000000,"profit":false}] |
| Gross Margin | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Operating Expenses | 237.32M | 135.87M | 187.53M | 263.46M | 236.16M | [{"date":"2021-12-31","value":90.08,"profit":true},{"date":"2022-12-31","value":51.57,"profit":true},{"date":"2023-12-31","value":71.18,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":89.64,"profit":true}] |
| Operating Income | (237.32M) | (135.87M) | (188.19M) | (263.46M) | (241.16M) | [{"date":"2021-12-31","value":-23732300000,"profit":false},{"date":"2022-12-31","value":-13587000000,"profit":false},{"date":"2023-12-31","value":-18819400000,"profit":false},{"date":"2024-12-31","value":-26346400000,"profit":false},{"date":"2025-12-31","value":-24115600000,"profit":false}] |
| Total Non-Operating Income/Expense | 11.00K | 9.53M | (30.85M) | 39.79M | 9.48M | [{"date":"2021-12-31","value":0.03,"profit":true},{"date":"2022-12-31","value":23.94,"profit":true},{"date":"2023-12-31","value":-77.54,"profit":false},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":23.83,"profit":true}] |
| Pre-Tax Income | (237.31M) | (130.90M) | (235.66M) | (243.61M) | (236.80M) | [{"date":"2021-12-31","value":-23731200000,"profit":false},{"date":"2022-12-31","value":-13090400000,"profit":false},{"date":"2023-12-31","value":-23565700000,"profit":false},{"date":"2024-12-31","value":-24360900000,"profit":false},{"date":"2025-12-31","value":-23679800000,"profit":false}] |
| Income Taxes | 301.44K | (4.56M) | 268.00K | 178.00K | 130.00K | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1513.06,"profit":false},{"date":"2023-12-31","value":88.91,"profit":true},{"date":"2024-12-31","value":59.05,"profit":true},{"date":"2025-12-31","value":43.13,"profit":true}] |
| Income After Taxes | (237.61M) | (126.34M) | (235.93M) | (243.79M) | (236.93M) | [{"date":"2021-12-31","value":-23761344200,"profit":false},{"date":"2022-12-31","value":-12634300000,"profit":false},{"date":"2023-12-31","value":-23592500000,"profit":false},{"date":"2024-12-31","value":-24378700000,"profit":false},{"date":"2025-12-31","value":-23692800000,"profit":false}] |
| Income From Continuous Operations | (237.31M) | (130.90M) | (235.93M) | (243.79M) | (236.93M) | [{"date":"2021-12-31","value":-23731200000,"profit":false},{"date":"2022-12-31","value":-13090400000,"profit":false},{"date":"2023-12-31","value":-23592500000,"profit":false},{"date":"2024-12-31","value":-24378700000,"profit":false},{"date":"2025-12-31","value":-23692800000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (237.31M) | (130.90M) | (235.93M) | (243.79M) | (236.93M) | [{"date":"2021-12-31","value":-23731200000,"profit":false},{"date":"2022-12-31","value":-13090400000,"profit":false},{"date":"2023-12-31","value":-23592500000,"profit":false},{"date":"2024-12-31","value":-24378700000,"profit":false},{"date":"2025-12-31","value":-23692800000,"profit":false}] |
| EPS (Diluted) | - | - | (2.13) | (1.53) | (1.45) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-212.83,"profit":false},{"date":"2024-12-31","value":-153,"profit":false},{"date":"2025-12-31","value":-145,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| NMRA | |
|---|---|
| Cash Ratio | 4.88 |
| Current Ratio | 5.09 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| NMRA | |
|---|---|
| ROA (LTM) | -58.11% |
| ROE (LTM) | -121.21% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| NMRA | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.54 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.46 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| NMRA | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 4.64 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Neumora Therapeutics, Inc. (NMRA) share price today is $1.67
Yes, Indians can buy shares of Neumora Therapeutics, Inc. (NMRA) on Vested. To buy
Yes, you can purchase fractional shares of Neumora Therapeutics, Inc. (NMRA) via the Vested app. You can start investing in Neumora Therapeutics, Inc. (NMRA) with a minimum investment of $1.
You can invest in shares of Neumora Therapeutics, Inc. (NMRA) via Vested in three simple steps:
The 52-week high price of Neumora Therapeutics, Inc. (NMRA) is $3.65. The 52-week low price of Neumora Therapeutics, Inc. (NMRA) is $0.66.
The price-to-earnings (P/E) ratio of Neumora Therapeutics, Inc. (NMRA) is
The price-to-book (P/B) ratio of Neumora Therapeutics, Inc. (NMRA) is 4.64
The dividend yield of Neumora Therapeutics, Inc. (NMRA) is 0.00%
The market capitalization of Neumora Therapeutics, Inc. (NMRA) is $327.95M
The stock symbol (or ticker) of Neumora Therapeutics, Inc. is NMRA
Consider the share price of Neumora Therapeutics, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Neumora Therapeutics, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Neumora Therapeutics, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Neumora Therapeutics, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Neumora Therapeutics, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Neumora Therapeutics, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
